Live
FierceBiotechVedana Therapeutics surfaces with $46M to develop next generation of migraine prevention therapiesFierceBiotechUniQure stock surges after FDA U-turn clears path to gene therapy filingPharmaVoiceWhy ivermectin is in the limelight againClinical OMICsPhilippe Pouletty: Turning Europe’s Life Science Startups Into World LeadersBioWorldLundbeck patents new orexin OX2 receptor agonistsBioWorldZealand Pharma reports IL-23R antagonistsBioWorldChengdu Chipscreen Pharmaceutical synthesizes new MOGAT2 inhibitorsBioWorldPRMT5 inhibitors reported in Prospect Therapeutics patentBioWorldIgnis Therapeutics discloses new dopamine D1 receptor PAMsLabiotechEight in vivo CAR T biotechs to follow closelyFierceBiotech'Biopharma ecosystem is back to full health,' fueled by M&A: PwCFierceBiotechJazz, AbCellera strike TCE discovery and development deal worth up to $792M per drug
Lonza News Jan 29, 2026

Narrow-Moat Lonza's Long-Term Outlook Driven by Strong Outsourced Drug Manufacturing Demand - Morningstar

Narrow-Moat Lonza's Long-Term Outlook Driven by Strong Outsourced Drug Manufacturing Demand - Morningstar

Original
Body unavailable. Use the original source.